In addition, we intend to develop new patentable formulations, use new delivery methods and seek regulatory approval for new indications of existing drugs. We may also acquire companies with complementary products. Large multinational companies dominate the U.S. prescription pharmaceutical market. Pfizer Inc. Since 1992, we have introduced 13 products. We promote our products through our nationwide sales and marketing force of approximately 150 professionals, targeting high-prescribing primary care and specialty physicians such as cardiologists, gastroenterologists, gynecologists and pediatricians.
Third parties manufacture all of our products.
We have marketed Tanafed, a liquid cold and allergy product primarily for children, since 1993. In January 1999, we acquired the gastrointestinal products Robinul and Robinul Forte, indicated for use in the treatment of peptic ulcer, from American Home Products Corporation. In July and October 1999, we acquired marketing rights from Pohl-Boskamp and Aventis, respectively, to Nitrolingual, a product used for the acute relief or prevention of chest pain resulting from heart disease. In February 2000, we launched an improved version of Nitrolingual called Nitrolingual Pumpspray. In April 2000, we acquired from Pfizer U.S. rights to market, distribute and sell Ponstel, a product used for the relief of mild to moderate pain and pain associated with menstruation.